Skip to main content

Table 2 Resource costs parameters used in Markov model (THB as of 2009 value)

From: Is a HIV vaccine a viable option and at what price? An economic evaluation of adding HIV vaccination into existing prevention programs in Thailand

Parameters Distribution Mean SE References
Costs of prevention program     
Annual costs of existing prevention programs Gamma 24   [27, 28]
Cost of HIV vaccine per course Gamma 3,500   [12]
Individual cost of community engagement Gamma 937*   
Cost of HIV screening (ELISA) for vaccine acceptance Gamma 125   [47]
Cost of pre-counselling for all vaccinations Gamma 141   [47]
Cost of post-counselling for vaccine acceptance Gamma 58   [47]
Costs of treatment program     
Costs of asymptomatic treatment     
Laboratory cost for asymptomatic patient Gamma 8,155   [29]
Hospital service cost of asymptomatic patient Gamma 2,502   [29]
OPD cost of asymptomatic patient Gamma 2,502   [29]
Costs of symptomatic treatment     
Lab test cost for symptomatic patient Gamma 8,931   [29]
Opportunity infection treatment cost of symptomatic patient Gamma 4,739   [29]
Hospital service cost of symptomatic patient Gamma 9,104   [29]
OPD cost of symptomatic patient Gamma 2,502   [29]
IPD cost of symptomatic patient Gamma 6,227   [29]
Costs of AIDS treatment     
Opportunity infection treatment cost of AIDS patient Gamma 4,739   [29]
Hospital service cost of AIDS patient Gamma 9,104   [29]
OPD cost of AIDS patient Gamma 2,502   [29]
IPD cost of AIDS patient Gamma 6,227   [29]
Annual drug costs of the first-line ART regimens (mg): Gamma 8,184 1,858  
1. d4T(30)+3TC(150)+NVP(200) or     
2. d4T(30) + 3TC(150) + EFV (600) or     
3. AZT(100/200/250/300)+3TC(150)+NVP(200) or     
4. AZT(100/200/300)+3TC(150)+EFV(600)     
Annual drug costs of the second-line ART regimens (mg): Gamma 32,478 5,772  
1. ddI(250)+3TC(150)+NVP(200) or     
2. ddI(250)+3TC(150)+EFV(600) or     
3. TDF(300)+3TC(150)+NVP(200) or     
4. TDF(300)+3TC(150/300)+EFV(600)     
Annual drug costs of the third-line ART regimens (mg): Gamma 15,682 2,080  
1. AZT(100/200/300)+3TC(150)+Boosted PIs or     
2. d4T(30)+3TC(150)+Boosted PIs or     
3. TDF(300)+3TC(150)+Boosted PIs or     
4. ddI(250)+3TC(150)+Boosted PIs or     
5. AZT(100/200/300)+ddI(250)+Boosted PIs or     
6. AZT(100/200/300)+TDF(300)+Boosted PIs or     
7. AZT(100/200/300)+3TC(150)+TDF(300)+Boosted PIs     
Annual costs of lab test of first-line ART regimen in the first year Gamma 7,671   [48]
Annual costs of lab test of first-line ART regimen in subsequence years Gamma 4,210   [48]
Annual costs of lab test of the second-line ART regimen Gamma 4,140   [48]
Annual costs of lab test of the third-line ART regimen Gamma 4,163   [48]
  1. SE: standard error; THB: Thai baht; OPD: outpatient department; IPD: inpatient department; ART: antiretroviral treatment; d4T: stavudine; 3TC: lamivudine; NVP: nevirapine; EFV: efavarenze; AZT; zidovudine; TDF: tenofovir; ddI: dianosine; and PIs: protease inhibitors.
  2. *Nakorn Premsri, National Vaccine Committee Office, Department of Disease Control, Ministry of Public Health, personal communication, August 25, 2009.
  3. Thanapat Laowahutanon, AIDS office, Bureau of Disease Management, National Health Security Office, personal communication, August 20, 2009.
  4. Boosted PIs were recommended by National Health Security Office as follows: the first-line PIs regimen, LPV/r-- lopinavir (200 mg) + ritonavir(50 mg) or IDV/r-- indinavir (400 mg) + ritonavir (100 mg) and the second-line PIs regimen, ATV/r-- atazanavir (150 mg)+ ritonavir (100 mg)